LOGIN OR REGISTER
Course Library

Expert Panel Discussion: Complicated Treatment Decisions in NSCLC

Hematology-Oncology
Credits:
1 AMA PRA Category 1 Credit(s) ™
Launch Date:
December 27, 2017
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

oncologists, hematologists

Relevant Terms:

Oncology, NSCLC, Hematology

Joel Neal, MD, PhD

Joel Neal, MD, PhD
Assistant Professor of Medicine - Oncology
Stanford University Medical Center

Dr. Neal holds a medical degree and a doctoral degree in Tumor Cell Biology from Northwestern University in Chicago, Illinois. Subsequently, he completed a fellowship in oncology, rotating through the Dana-Farber Cancer Institute and Massachusetts General Hospital in Boston, Massachusetts. He is currently an Assistant Professor in the Division of Oncology at the Stanford Cancer Institute at Stanford University in Palo Alto, California. Dr Neal’s primary clinical interest is in thoracic oncology. In addition to maintaining an active practice, he focuses on the design and conduct of clinical trials involving targeted therapies and immunotherapy for lung cancer and mesothelioma. He has published dozens of articles in the field of thoracic oncology, including in Lancet Oncology, Nature Medicine, and the Journal of Clinical Oncology. He is a member of the International Association of the Study of Lung Cancer (IALSC), is a study chair and thoracic core committee member within the ECOG-ACRIN cooperative group, and has presented at a number of American Society of Clinical Oncology (ASCO) annual meetings. 

Lecia V. Sequist, MD, MPH

​Lecia V. Sequist, MD, MPH 
Associate Professor, Department of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center

Dr. Sequist is originally from Michigan and studied chemistry at Cornell University. She received her MD from Harvard Medical School and trained in internal medicine at the Brigham and Women's Hospital and in hematology/oncology at the DFCI/MGH joint program, where she also received an MPH from the Harvard School of Public Health. She joined the faculty of the Center for Thoracic Cancers at the Massachusetts General Hospital Cancer Center in 2005 and has an active clinical and translational research career, as well as a busy practice caring for patients with lung cancer. She is currently an Associate Professor of Medicine at Harvard Medical School and the Mary B. Saltonstall Endowed Chair in Oncology at MGH. Dr. Sequist's research focuses on studying novel targets and targeted agents for lung cancer treatment, particularly those that target the epidermal growth factor receptor (EGFR) and in detecting and studying the significance of tumor cells circulating in the bloodstream (circulating tumor cells, or CTCs). She aims to develop treatment algorithms for lung cancer that are more personalized than current strategies, utilizing targeted therapies specific to the patients' cancer genotypes, and understanding how this may change over the courses of the disease.

Nathan A. Pennell, MD, PhD

​Nathan A. Pennell, MD, PhD
Associate Professor and Director
Lung Cancer Medical Oncology Program
Cleveland Clinic Taussig Cancer Institute

 
Dr. Pennell is a board certified medical oncologist who joined the staff of the Cleveland Clinic Taussig Cancer Institute in 2008. He specializes in the treatment of thoracic malignancies with a focus on lung cancer, and was appointed director of the TCI lung cancer medical oncology program in 2010. He is an associate professor medical oncology at the Cleveland Clinic Lerner College of Medicine. Dr. Pennell’s research interests include clinical trials using novel therapies, with a goal of facilitating the movement of new treatments from the laboratory to the clinic.
 
 
 
1. Assess the most current safety and efficacy data and guideline recommendations associated with evidence-based targeted therapies 
2. Select the most appropriate patients for anti-VEGF therapy based on individualized characteristics, comorbidities, risk factors, and current clinical evidence
3. Identify the role of novel immunotherapies in the use of individualized targeted therapies for advanced NSCLC
4. Incorporate updated genomic testing guidelines and streamlined algorithms for evidence-based targeted treatments of NSCLC patients

THIS ACTIVITY IS BASED ON A FACULTY DISCUSSION HELD IN SEPTEMBER 2017.
 
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Academy of CME, Inc., (Academy) and CME Matters LLC. The Academy is accredited by the ACCME to provide continuing medical education for physicians.

The Academy designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CME Matters. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
 

Disclosures
All faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. Disclosures are as follows:

Joel Neal, MD, PhD has affiliations with CARET Physicians Resource Management, Clovis Oncology, Nektar Therapeutics, and Boehringer Ingelheim (Consultant – marketing); Argule, Boehringer Ingelheim, Exelixis, Genentech/Roche, Merck, Nektar Therapeutics, and Novartis (Grant Recipient).
 
 
 
 
Lecia V. Sequist, MD, MPH has affiliations with AstraZeneca, Pfizer, Novartis, Merrimack, Boehringer Ingelheim, Genentech (Advisory Board/Scientific Consultant); Novartis, Boehringer Ingelheim, Merrimack, and Genentech (Grant Recipient - all to institution) 
 
 
 
 
 
Nathan A. Pennell, MD, PhD has affiliations with AstraZeneca, Eli Lilly, and Regeneron (Advisory Board) 
 
 
 
 
 
 
 
Cathy Pagano, CHCP and Anita Misra-Press (CME Matters LLC) and John JD Juchniewicz, MCIS, CHCP (American Academy of CME, Inc.) have disclosed that they have no relevant financial relationships specific to the subject matter within the past 12 months.  

This activity will review off-label or investigational information.
 
This activity has been supported by an unrestricted educational grant from Genentech.
 

Contact
For any questions, please contact: CEServices@academycme.org
 
The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CME Matters. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
 
 
 
 
 
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
 		 Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.



 

Schedule an event with a Standardized Patient
×